Organon (OGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of ten director nominees for the board, each recommended for approval.
Advisory approval of executive compensation for named executive officers is on the agenda.
Proposal to amend and restate the 2021 Incentive Stock Plan is up for shareholder approval.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 is included.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Ten director nominees are presented for election, including individuals with medical, executive, and governance backgrounds.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
An amendment and restatement of the 2021 Incentive Stock Plan is proposed for approval.
Latest events from Organon
- Shareholders to vote on directors, executive pay, incentive plan, and auditor amid strong governance.OGN
Proxy filing24 Apr 2026 - 2025 revenue fell 3% to $6.2B; 2026 outlook is flat with margin and policy headwinds.OGN
Q4 202512 Feb 2026 - All board proposals passed, with 2024 revenue up 3% and a focus on cost and debt reduction.OGN
AGM 20253 Feb 2026 - Q2 revenue flat at $1.61B; guidance and cash flow targets reaffirmed despite margin declines.OGN
Q2 20242 Feb 2026 - All proposals passed, with strong revenue growth and a continued focus on women's health initiatives.OGN
AGM 202431 Jan 2026 - Revenue down 7% in Q1 2025; guidance, deleveraging, and dividend reset reaffirmed.OGN
Q1 202519 Jan 2026 - 2024 revenue rose 3% ex-FX, with margin strength and Women's Health and biosimilar growth.OGN
Q4 202419 Jan 2026 - Q2 2025 revenue down 1%, guidance raised, leverage reduction and portfolio growth on track.OGN
Q2 202519 Jan 2026 - Q3 revenue up 4–5%, net income surged to $359M, and 2024 guidance was raised.OGN
Q3 202417 Jan 2026